These analyses suggest that AIL can effectively inhibit the RANKL and IL-1β expression in BC bone metastasis tissues by upregulating FOXP3 in a concentration-dependent manner, and ultimately inhibit the osteoclast differentiation in vivo and the progression of the BC bone metastasis. Here, IL1B is linked to breast cancer.